RATIO-LISINOPRIL Z TABLET

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

LISINOPRIL

Available from:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATC code:

C09AA03

INN (International Name):

LISINOPRIL

Dosage:

10MG

Pharmaceutical form:

TABLET

Composition:

LISINOPRIL 10MG

Administration route:

ORAL

Units in package:

100/500

Prescription type:

Prescription

Therapeutic area:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Product summary:

Active ingredient group (AIG) number: 0121550001; AHFS:

Authorization status:

CANCELLED POST MARKET

Authorization date:

2014-09-19

Summary of Product characteristics

_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 1 of 39 _
PRODUCT MONOGRAPH
RATIO-LISINOPRIL Z
Lisinopril
Tablets 5 mg, 10 mg and 20 mg
USP
Angiotensin Converting Enzyme Inhibitor
ratiopharm inc.
Canada J7J 1P3
DATE OF PREPARATION: SEPTEMBER 20, 2007
CONTROL NUMBER: 110419
_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
……………………………………………………..4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND
ADMINISTRATION.............................................................................
16
SYMPTOMS AND TREATMENT OF OVERDOSAGE
............................................... 19
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND
STABILITY.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 22
PART II: SCIENTIFIC INFORMATION
..............................................................................
23
PHARMACEUTICAL
INFORMATION.........................................................................
23
CLINICAL
TRIALS.........................................................................................................
24
DETAILED
PHARMACOLOGY...............................................................